NEOGEN CORP NEOG

Healthcare SIC 2835 - In Vitro & In Vivo Diagnostic Substances NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Neogen Corporation and its subsidiaries develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Our Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. These products also ensure the general hygiene of the food manufacturing environment. We also have products to determine food quality and nutritional components. The majority of the test kits are consumables, single-use culture, immunoassay and nucleic acid detection products that rely on proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. Our line of food safety services also includes advanced software systems that help testers objectively analyze, store and identify emerging issues from their results from multiple locations over extended periods.

Last close 12.19 2026-10-23
Market cap $2.66B 2026-05-31 share count
52-week range 5.37 - 14.26

Valuation FY2025 figures against the last close

P/S3.1x
P/E—
P/FCF83.3x
EV/EBITDA34.5x
Dividend yield—
Diluted EPS-0.04

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • International
  • Domestic
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2025 International, FY2025: 445.3M (51.2%) 51% International Domestic, FY2025: 425.1M (48.8%) 49% Domestic FY2024 International, FY2024: 448.7M (50.2%) 50% Domestic, FY2024: 446M (49.8%) 50% FY2023 International, FY2023: 459M (49.7%) 50% Domestic, FY2023: 465.2M (50.3%) 50%
Region FY2025FY2024FY2023
International $445.3M $448.7M $459.0M
Domestic $425.1M $446.0M $465.2M

As the company reported it, from the “Disaggregated Revenue by Geographic Location (Detail)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $870.4M$894.7M$924.2M$822.4M$527.2M$468.5M$418.2M$414.2M$397.9M$358.3M
Cost of revenue $461.9M$473.3M$460.3M$416.5M$284.1M$253.4M$221.9M$222.3M$211.7M$189.4M
Gross profit $408.5M$421.4M$463.9M$406.0M$243.0M$215.1M$196.3M$191.9M$186.3M$168.9M
R&D $18.4M$21.1M$22.5M$26.0M$17.0M$16.2M$14.8M$12.8M$10.9M$10.4M
SG&A $245.1M$218.2M$199.9M$201.2M$82.7M$51.2M$44.3M$40.8M$38.3M$34.2M
Total operating expenses $430.1M$1.48B$405.3M$368.4M$184.4M$140.9M$128.8M$123.8M$116.1M$104.0M
Operating income -$21.6M-$1.06B$58.6M$37.5M$58.6M$74.2M$67.5M$68.1M$70.2M$64.9M
Interest expense $24.1M$38.1M$42.2M$27.3M——————
Pre-tax income -$9.0M-$1.13B-$14.3M-$22.0M$60.2M$75.3M$72.3M$73.0M$73.5M$66.7M
Income tax $1.1M$41.1M$4.9M$828.0K$11.9M$14.4M$12.8M$12.8M$10.2M$22.7M
Net income -$7.9M-$1.09B-$9.4M-$22.9M$48.3M$60.9M$59.5M$60.2M$63.1M$43.8M
EPS, basic -0.04-5.03-0.04-0.120.450.570.570.581.230.87
EPS, diluted -0.04-5.03-0.04-0.120.450.570.560.571.210.86
Shares, diluted (wtd. avg.) 217.5M216.9M216.5M188.9M108.0M107.1M105.7M104.8M52.1M51.2M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $185.5M$129.0M$170.6M$163.2M$44.5M$75.6M$66.3M$41.7M$83.1M$77.6M
Short-term investments —$0$325.0K$82.3M$336.6M$305.5M$277.4M$225.8M$127.7M$66.1M
Receivables $146.8M$153.4M$173.0M$153.3M$99.7M$91.8M$84.7M$82.6M$79.1M$68.6M
Inventory $144.3M$190.8M$189.3M$133.8M$122.3M$100.7M$95.1M$86.0M$76.0M$73.1M
Total current assets $604.6M$576.9M$589.2M$585.9M$626.8M$591.5M$537.4M$449.5M$375.8M$293.0M
Property, plant and equipment $329.8M$339.1M$277.1M$198.7M$110.6M$100.5M$78.7M$74.8M$73.1M$61.7M
Goodwill $1.05B$1.06B$2.14B$2.14B$142.7M$131.5M$110.3M$103.6M$99.6M$104.8M
Other intangibles $1.32B$1.41B$1.51B$1.59B$92.1M$76.8M$51.4M$52.1M$54.7M$54.6M
Total assets $3.35B$3.44B$4.55B$4.55B$992.9M$920.2M$797.2M$695.7M$618.0M$528.4M
Accounts payable $79.1M$79.6M$83.1M$76.7M$34.6M$23.9M$25.6M$19.1M$20.8M$16.2M
Short-term debt $0$19.3M$2.4M———————
Total current liabilities $158.2M$174.0M$154.3M$145.5M$77.8M$53.6M$48.5M$38.3M$38.7M$36.0M
Long-term debt $793.7M$874.8M$888.4M$885.4M——————
Total liabilities $1.25B$1.37B$1.40B$1.42B$105.6M$79.8M$72.0M$57.8M$57.8M$56.7M
Retained earnings -$544.3M-$536.4M$555.6M$565.0M$587.9M$539.6M$478.7M$419.2M$359.1M$295.9M
Total equity $2.09B$2.07B$3.14B$3.13B$887.4M$840.4M$725.2M$637.9M$560.2M$471.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $83.2M$58.2M$35.3M$41.0M$68.0M$81.1M$85.9M$63.8M$69.1M$60.3M
Depreciation and amortisation $116.3M$119.5M$116.7M$88.4M$23.7M$21.0M$18.4M$17.6M$17.1M$14.7M
Stock-based compensation $13.4M$17.3M$13.8M$10.2M$7.2M$6.4M$6.5M$5.5M$4.9M$5.3M
Capital expenditure $51.3M$104.6M$111.4M$65.8M$24.4M$26.7M$24.1M$14.7M$20.9M$14.6M
Investing cash flow $70.5M-$99.2M-$29.3M$201.0M-$97.2M-$105.6M-$88.8M-$119.1M-$83.1M-$62.1M
Financing cash flow -$99.4M-$1.6M$1.9M-$118.1M$6.8M$33.5M$29.4M$13.9M$22.8M$25.1M
Buybacks ———————$3.1M——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-360742.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -2B -1B 0 1B Revenue, FY2016: 358.3M Gross profit, FY2016: 168.9M Net income, FY2016: 43.8M Revenue, FY2017: 397.9M Gross profit, FY2017: 186.3M Net income, FY2017: 63.1M Revenue, FY2018: 414.2M Gross profit, FY2018: 191.9M Net income, FY2018: 60.2M Revenue, FY2019: 418.2M Gross profit, FY2019: 196.3M Net income, FY2019: 59.5M Revenue, FY2020: 468.5M Gross profit, FY2020: 215.1M Net income, FY2020: 60.9M Revenue, FY2021: 527.2M Gross profit, FY2021: 243M Net income, FY2021: 48.3M Revenue, FY2022: 822.4M Gross profit, FY2022: 406M Net income, FY2022: -22.9M Revenue, FY2023: 924.2M Gross profit, FY2023: 463.9M Net income, FY2023: -9.4M Revenue, FY2024: 894.7M Gross profit, FY2024: 421.4M Net income, FY2024: -1.1B Revenue, FY2025: 870.4M Gross profit, FY2025: 408.5M Net income, FY2025: -7.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $358.3M $397.9M $414.2M $418.2M $468.5M $527.2M $822.4M $924.2M $894.7M $870.4M
Gross profit $168.9M $186.3M $191.9M $196.3M $215.1M $243.0M $406.0M $463.9M $421.4M $408.5M
Net income $43.8M $63.1M $60.2M $59.5M $60.9M $48.3M -$22.9M -$9.4M -$1.09B -$7.9M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Shareholder vote Item 5.07

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2835

TickerCompanyMarket capP/ERevenue growth
IDXX IDEXX LABORATORIES INC /DE $44.15B 42.8x 10.4%
LNTH Lantheus Holdings, Inc. $6.51B 29.3x 0.5%
CLDX Celldex Therapeutics, Inc. $2.30B — -78.0%
NTLA Intellia Therapeutics, Inc. $1.57B — 16.9%
QDEL QuidelOrtho Corp $941.5M — -1.9%
ACHV ACHIEVE LIFE SCIENCES, INC. $667.8M — —
MYGN MYRIAD GENETICS INC $556.7M — -1.6%
TKNO Alpha Teknova, Inc. $344.7M — 7.4%